Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TPN Electrolytes** is a sterile, phosphate-free, hypertonic intravenous multiple-electrolyte concentrate containing sodium chloride, sodium acetate anhydrous, magnesium chloride, potassium chloride, and calcium chloride. Developed and marketed by Pfizer through Hospira, it is diluted into total parenteral nutrition solutions to maintain electrolyte homeostasis and prevent or correct deficiencies of sodium, potassium, calcium, magnesium, chloride, and acetate in adults receiving central venous TPN. Its therapeutic activity is electrolyte replacement rather than selective binding to a discrete molecular target; acetate provides a metabolizable anion that can contribute to systemic bicarbonate generation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + sodium acetate anhydrous + magnesium chloride + potassium chloride + calcium chloride.